PT - JOURNAL ARTICLE AU - Greg Dropkin TI - COVID-19 UK Lockdown Forecasts and R<sub>0</sub> AID - 10.1101/2020.04.07.20052340 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.07.20052340 4099 - http://medrxiv.org/content/early/2020/04/10/2020.04.07.20052340.short 4100 - http://medrxiv.org/content/early/2020/04/10/2020.04.07.20052340.full AB - Introduction The first reported UK case of COVID-19 occurred on 31 January 2020, and a lockdown of unknown duration began on 24 March. One model to forecast disease spread depends on clinical parameters and transmission rates. Output includes the basic reproduction number R0 and the log growth rate r in the exponential phase.Methods UK data on reported deaths is used to estimate r. A likelihood for the transmission parameters is defined from a gaussian density for r using the mean and standard error of the estimate. Parameter samples from the Metropolis-Hastings algorithm lead to an estimate and credible interval for R0 and forecasts for severe and critical cases, and deaths during a lockdown.Results In the exponential phase, the UK growth rate for log(deaths) is r = 0.224 with s.e. 0.005. R0 = 5.81 with 90% CI (5.08, 6.98). In a 12 week lockdown from 24 March with transmission parameters reduced to 20% of their previous values, around 63,000 severely ill patients will need hospitalisation by mid June, 37,000 critically ill will need intensive care, whilst over 81,000 are expected to die. Had the lockdown begun on 17 March around 16,500 severe, 9,250 critical cases and 18,500 deaths would be expected by early June. With 10% transmission, severe and critical cases peak in April.Discussion The R0 estimate is around twice the value quoted by the UK government. The NHS faces extreme pressures, even if transmission is reduced ten-fold. An earlier lockdown could have saved many lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK data on COVID-19 cases and deaths is freely available from Public Health England https://fingertips.phe.org.uk/documents/Historic%20COVID-19%20Dashboard%20Data.xlsx